Financial Performance - The company's revenue for Q1 2023 was ¥57,821,862.92, a decrease of 28.17% compared to ¥80,498,706.84 in the same period last year[5] - The net profit attributable to shareholders was -¥4,957,020.00, representing a decline of 139.99% from ¥12,394,501.00 in the previous year[5] - The net profit for the period was -¥5,195,591.79, a decrease of 139.43% compared to ¥13,177,021.23 in the same period last year, primarily due to reduced revenue[12] - Basic and diluted earnings per share were both -¥0.0327, down 140.02% from ¥0.0817 in the previous year[5] - Net profit for Q1 2023 was a loss of ¥5,195,591.79, compared to a profit of ¥13,177,021.23 in Q1 2022, indicating a significant decline[22] - Other comprehensive income after tax for Q1 2023 was ¥1,025,634.80, compared to a loss of ¥381,671.00 in Q1 2022[22] - The company reported a total comprehensive loss of ¥4,169,956.99 for Q1 2023, contrasting with a comprehensive income of ¥12,795,350.23 in the previous year[23] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 82.28%, amounting to ¥6,383,061.96 compared to ¥36,022,107.70 in the same period last year[5] - Cash inflow from operating activities was ¥65,240,844.72, down 45.0% from ¥118,694,498.59 in the previous year[24] - The cash flow from operating activities decreased by 29.00% year-over-year, indicating potential challenges in operational efficiency[26] - The company reported a total cash inflow from investment activities of ¥145,876.72, a decrease of 99.64% from ¥40,447,731.48 in Q1 2022[26] - The total cash outflow from financing activities was ¥1,775,525.26, compared to ¥496,017.55 in Q1 2022, reflecting a significant increase in cash outflows[26] - The company did not report any cash inflow from financing activities in Q1 2023, which may impact future liquidity[26] - The cash and cash equivalents at the end of Q1 2023 stood at ¥355,359,287.63, an increase from ¥245,445,675.42 at the end of Q1 2022[26] - The total cash and cash equivalents decreased by ¥87,045,890.02 in Q1 2023, compared to a decrease of ¥109,782,967.87 in Q1 2022, showing a slight improvement in cash management[26] - The company’s interest, fees, and commissions paid in cash amounted to ¥26,136,030.74, an increase from ¥23,775,864.77 in Q1 2022, indicating rising financial costs[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,074,507,775.62, a slight decrease of 0.40% from ¥1,078,822,798.36 at the end of the previous year[5] - The total liabilities as of Q1 2023 were ¥84,303,638.41, slightly up from ¥84,060,804.00 in the previous year[22] - The total equity attributable to shareholders of the parent company was ¥984,798,550.53, a slight decrease from ¥986,821,784.04[22] - Total current assets increased slightly from ¥774,703,256.65 to ¥778,273,789.25, reflecting a growth of about 0.7%[18] - Total non-current assets decreased from ¥304,119,541.71 to ¥296,233,986.37, a decline of about 2.6%[18] Operational Expenses - Total operating costs for Q1 2023 were ¥60,947,102.16, down from ¥64,188,647.01, reflecting a reduction of 5.3%[21] - Sales expenses increased by 35.51% to ¥5,407,111.94, primarily due to increased promotional expenses for the U.S. subsidiary[12] - Research and development expenses increased to ¥15,270,788.62, up from ¥11,790,554.10, representing a rise of 29.1% year-over-year[22] Investments and Future Outlook - The company has ongoing investments in new technologies and products, although specific details were not disclosed in the provided content[15] - Future outlook includes potential market expansion and strategic initiatives, but specific targets or timelines were not detailed in the available information[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,847[14] - The largest shareholder, DeTai International Investment Group, holds 28.10% of shares, totaling 42,580,000 shares[14] Financial Assets - The company reported a significant increase in trading financial assets, which rose by 1286.95% to ¥97,309,338.17 due to the purchase of structured deposits[10] - The company experienced a 70.19% decline in investment income, which fell to ¥137,430.86 due to unexpired structured financial products[12]

Financial Performance - The net profit attributable to shareholders for 2022 decreased by 69.87% compared to the previous year, primarily due to a reduction in operating income despite stable gross margins [5]. - The company achieved a net profit of RMB 200 million in 2022, an increase of 10% compared to the previous year [24]. - The company's operating revenue for 2022 was ¥319,761,152.14, a decrease of 18.21% compared to ¥390,976,202.73 in 2021 [30]. - The net profit attributable to shareholders for 2022 was ¥22,573,646.90, down 69.87% from ¥74,909,120.89 in 2021 [30]. - The basic earnings per share for 2022 was ¥0.1489, a decline of 73.63% from ¥0.5647 in 2021 [30]. - The total operating revenue for 2022 was ¥319,761,152.14, a decrease of 18.21% compared to ¥390,976,202.73 in 2021 [103]. - Revenue from laser products amounted to ¥206,565,427.24, accounting for 64.60% of total revenue, down 14.99% from ¥242,978,177.41 in 2021 [103]. - The gross profit margin was approximately 52.58%, indicating a solid foundation for healthy development [87]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 25% compared to the previous year [184]. Research and Development - The company increased its investment in R&D and management to expand into emerging markets such as medical, photovoltaic, and overseas markets, which impacted current performance but is expected to yield positive results in the future [5]. - The company is investing RMB 100 million in R&D for new laser technologies, aiming to launch two new products in 2023 [24]. - The R&D expense ratio was approximately 16.98%, with rapid development in high-value medical devices and photovoltaic sectors, diversifying revenue sources [87]. - The company has established R&D centers in both the U.S. and China, leveraging local industry cluster characteristics for innovation [74]. - The company has initiated the development of new products, including TOPCON laser doping equipment and IBC battery opening equipment, to meet market demands and enhance competitiveness [115]. - The company has allocated a budget of 50 million yuan for R&D in new medical imaging technologies in 2023 [157]. - Research and development efforts have led to the filing of 5 new patents in laser technology, enhancing the company's competitive edge [184]. Market Expansion and Strategy - INNO LASER plans to expand its market presence in North America and Europe, targeting a 30% increase in international sales by 2024 [24]. - The company aims to strengthen market research and innovation-driven development to mitigate risks from macroeconomic uncertainties and industry competition [8][9]. - The company plans to focus on optimizing product design and procurement strategies to enhance efficiency in response to intensified competition in certain product lines [9]. - The company plans to expand its market presence by entering the Southeast Asian market, targeting a 15% market share by 2025 [156]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market reach [156]. - The company aims to enhance its market share and penetration rate, focusing on industrial applications and biomedical applications as key growth areas [143]. Operational Efficiency and Cash Flow - The net cash flow from operating activities significantly increased during the reporting period, aiding in risk prevention and sustainable development [5]. - The net cash flow from operating activities increased significantly by 322.88% to ¥107,192,250.37 in 2022, compared to ¥25,347,886.34 in 2021 [30]. - The company’s investment activities generated a net cash flow of -3,792,237.94 CNY, an improvement of 95.20% compared to the previous year [118]. - The company aims to improve operational efficiency by 10% through the implementation of advanced manufacturing technologies [184]. Risk Management - The company does not face significant risks regarding its ongoing operations, and its core competitiveness and main financial indicators have not experienced major adverse changes [5]. - The company does not anticipate significant risks related to industry overcapacity, continuous decline, or technological substitution [5]. - The company recognizes macroeconomic uncertainties and industry competition as potential risks and plans to strengthen market research and innovation-driven development [151]. - The company maintains a cautious investment approach in response to increased operational risks and market demand slowdown [134]. Corporate Governance - The company operates independently from its controlling shareholder, with no guarantees provided to the controlling shareholder or its affiliates during the reporting period [161]. - The board of directors consists of 7 members, including 3 independent directors, who actively participate in training and decision-making processes [162]. - The supervisory board has 3 members, including 1 employee supervisor, ensuring compliance and protecting shareholder rights [164]. - The company has established a comprehensive investor relations management system to ensure transparent and timely information disclosure [166]. - The company has not faced any penalties from securities regulatory agencies in the past three years [189]. Product Development and Innovation - The company has developed a "dual-band femtosecond laser stent micro-processing system," establishing a comprehensive capability in equipment, processes, and material applications for high-value medical implants [57]. - The company’s laser products include DPSS Q-switched nanosecond lasers and ultrafast lasers, covering various wavelengths from infrared to deep ultraviolet [63]. - The company is committed to developing innovative products and applications by integrating cross-disciplinary expertise in light, machinery, electricity, computing, and chemistry [99]. - The company has established a strategic partnership with leading healthcare institutions to drive innovation in medical applications [156]. Financial Management - The total pre-tax remuneration for directors, supervisors, and senior management amounted to CNY 6.4165 million [190]. - The company approved the 2022 Restricted Stock Incentive Plan during the board meeting on March 23, 2022 [191]. - The company plans to repurchase shares, with specific conditions and funding sources outlined, demonstrating commitment to shareholder value [192]. - The board has proposed to hold the 2023 first extraordinary general meeting, reflecting ongoing governance and shareholder engagement [193].

投资者关系活动记录表 编号：2022-10 证券代码：301021 证券简称：英诺激光 | --- | --- | --- | |----------------|--------------------------|---------------------------------| | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | 现场参观 | | | | 其他 电话会议 | | | 参与单位名称及 | 申万宏源：李 蕾、宗 | 亮； | | 人员姓名 | 国投瑞银：吉 莉、桑 | 俊、李 威、周宏成、吴默村、綦 | | | 缚鹏 | | | | 招商基金：徐张红、徐 | 生、李恭敏； | | | 中邮基金：沈路遥； | | | | 广发资管：田昕明； | | | | 东方阿尔法：程 可； | | | | 前海开源：范 洁； | | | | 恒大人寿：魏大千； | | | | 盈峰资本：张国平； | | | | 长城基金：张 | 坚、梁福睿； | | | 景林资产：张 钊； | | ...

投资者关系活动记录表 编号：02 证券代码：301021 证券简称：英诺激光 英诺激光科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 易方达基金邱天蓝、申万宏源证券李蕾、富国基 ...

投资者关系活动记录表 编号：03 证券代码：301021 证券简称：英诺激光 英诺激光科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 人员姓名 | 德邦证券倪正洋 | | | 时间 2021 | 年 7 月 27 日 | | | 地点 | 英诺激光南山办公室 | | | 上市公司接待人 员姓名 | 刘冬亮、陈文 | | | | | 公司以座谈形式和与会人员进行互动交流，沟通内容如 | | | 下： 一、介绍公司基本情况 | | | | 要问题如下： | 二、就投资者关心的问题与投资者进行交流，交流的主 ...

投资者关系活动记录表 编号：07 证券代码：301021 证券简称：英诺激光 英诺激光科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------------------|-------------------------------------------|---------------------------------------------------|------------|--------| | 投资者关系活动 \n类别 \n | □新闻发布会 □路演活动 \n□现场参观 \n□其他 | √特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 | | | | 参与单位名称及 | 盛博证券 首席分析师 | | 黄 | 颉 | | 人员姓名 | | 盛博证券 研究员 肖 | | 倩 | | | 盛博证券 | 研究员 | | 王迪恩 | | | | 盛博证券 公司和客户关系 蔡珊荣 | | | | | | 淡马锡 投资部总监 吴公彦 | | | | | 淡马锡 投资部总监 | | | 常宇亮 | | | 淡马锡 投资部副 ...

投资者关系活动记录表 编号：05 投资者关系活动 √特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 机构投资者： 人员姓名 广发证券 机械分析师 陈柏阳 招商基金 研究员 亢思汗 睿亿投资 投研副总监 袁晓昀 首创证券 投资经理助理 刘 洋 尚正基金 研究员 石竟成 尚道投资 研究员 王志飞 平安基金 研究员 张荫先 金信基金 基金经理 刘榕俊 彤源投资 研究员 郭 磊 晟平资产 研究员 黄彬彬 个人投资者： 腾湘、许燕、沈莉英 （排名不分先后） 证券代码：301021 证券简称：英诺激光 英诺激光科技股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|-----------------------------------------------------| | 时间 2021 | 年 9 月 7 日 | | 地点 | 深圳市南山区朗山二路清溢光电大厦 305 公司会议室 | | 上市公司接待人 | 董事长兼总经理 赵晓杰 | 1 投资者关系活动记录表 | --- | --- | --- ...

投资者关系活动记录表 编号：04 证券代码：301021 证券简称：英诺激光 英诺激光科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 人员姓名 | 安信证券江磊 | | | 时间 2021 | 年 7 月 28 日 | | | | 地点 英诺激光南山办公室 | | | 上市公司接待人 员姓名 | 刘冬亮、陈文 | | | | | 公司以座谈形式和与会人员进行互动交流，沟通内容如 | | | 下： 一、介绍公司基本情况 | 二、就投资者关心的问题与投资者进行交流，交流的主 | | | 要问题如下： | | | ...

投资者关系活动记录表 编号：01 证券代码：301021 证券简称：英诺激光 英诺激光科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------------|-------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 中信保诚基金郑伟、长城证券周申力、北大方正人寿孟婧、 | | 人员姓名 | | 兴业证券王俊、兴银理财郦莉、华富基金邓翔、煜德投资王 | | | | 秀平、长江证券赵志勇、长江证券臧雄、兴证全球基金李扬、 | | | | 朱雀基金杨洋、睿亿投 ...